---
title: "Key facts: ABUS Q1 $179.1M revenue; $169.7M net, $0.05 adj loss"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286379415.md"
description: "Arbutus Biopharma (ABUS) reported Q1 2026 revenue of $179.1M and net income of $169.7M, primarily due to a $178.7M license payment from the Genevant/Moderna settlement. The adjusted loss was $0.05 per share, slightly worse than the expected $0.03. Revenue decreased by 40% year-over-year. The stock has declined approximately 4.2% this quarter and 10.4% year-to-date, with a 12-month price target of $5.00."
datetime: "2026-05-14T07:54:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286379415.md)
  - [en](https://longbridge.com/en/news/286379415.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286379415.md)
---

# Key facts: ABUS Q1 $179.1M revenue; $169.7M net, $0.05 adj loss

-   Arbutus Biopharma (ABUS) reported Q1 2026 revenue $179.1M and net income $169.7M, driven by ~$178.7M noncontingent license payment tied to Genevant/Moderna settlement; holds ~16% of Genevant equity.1
-   Arbutus Biopharma (ABUS) Q1: adjusted loss $0.05/share vs ~$0.03 expected, revenue $179.7M down 40% YoY. Stock off ~4.2% this quarter, ~10.4% YTD; 12‑mo price target $5.00.2

### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [ABUS.US](https://longbridge.com/en/quote/ABUS.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)

## Related News & Research

- [Assessing Moderna (MRNA) Valuation After Flu Vaccine Data And Hantavirus Program Interest](https://longbridge.com/en/news/286642428.md)
- [Hantavirus: Is there a risk of another pandemic?](https://longbridge.com/en/news/286634066.md)
- [Bernstein Reaffirms Their Hold Rating on Moderna (MRNA)](https://longbridge.com/en/news/286092762.md)
- [Moderna Recognized by TIME as One of the World's Most Impactful Companies](https://longbridge.com/en/news/286159154.md)
- [Moderna Updates Bylaws and Confirms Governance Leadership](https://longbridge.com/en/news/285924997.md)